CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Summary
To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunction will improve renal function with increased sodium excretion, glomerular filtration rate and effective renal plasma flow and renal function reserve as compared to the response of placebo-treated subjects.
Timeline
- Start
- 2012-02
- Primary completion
- 2016-06-29
- Completion
- 2016-06-29
Outcome
Missed primary endpoint
registry analysis (superiority test); Candesartan vs Placebo; p = 0.26; t-test, 2 sided NCT01678794 ↗
registry analysis (superiority test); Candesartan vs Placebo; p = 0.67; t-test, 2 sided NCT01678794 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candesartan | Unknown | 16 mg | — |